BMPR2 mutation and clinical response to imatinib in a case of heritable pulmonary arterial hypertension

In patients with pulmonary arterial hypertension (PAH), limited real-world data are available on persistence to oral treprostinil therapy, particularly while transitioning from parenteral prostacyclins. 

An on-demand recording of PVRI’s December PH Community Call, featuring informal discussion on emerging science and patient-focused research in pulmonary hypertension. The session covers new insights into hypoxic PH mechanisms and exercise interventions in PAH, with expert-led moderation and open exchange.

Pulmonary arterial hypertension (PAH) is a progressive disease with significant morbidity and mortality. Due to nonspecific symptoms, diagnosis can be challenging and subject to substantial delays. Using data from Mayo Clinic′s electronic health records, we looked at causes of delayed diagnosis and whether earlier diagnosis means better outcomes.

Landmark trials of sotatercept in pulmonary arterial hypertension (PAH) excluded patients with significant cardiopulmonary comorbidities. To evaluate the real-world effectiveness and safety of sotatercept in patients with Group I PAH and cardiopulmonary comorbidities.